Drug targets a biomolecule that can directly bind to drugs and then react. Generally, the target refers to a protein related to the cause of disease. The focus of the target began with focusing on tumors and then began to spread to various fields. Introduction to MSLN/Mesothelin protein is a common target in medicine.

Mesothelin (MSLN) is a glycoprotein proteolytic protein by the Pre-pro-MSLN precursor, containing N-terminal signal peptide, mature megakaryocytic enhancement factor (MPF), furan cleavage sites, mature MSLN and GPI anchor sequences. The extracellular domain of MSLN contains multiple Ig-like domains and GPI anchor domains involved in intercellular interactions and signaling through binding with other proteins. Expression is limited in normal tissues, but it is significantly upregulated in various malignant tumors such as ovarian, breast, colorectal, and pancreatic cancer.

Overexpression of MSLN is sufficient to constitutively activate intracellular pathways where NF- κB, MAPK, and PI3k-kinase promote cell proliferation and resistance to apoptosis. Activation of the MSLN can trigger the activation of the Akt signaling pathway. Activation of Akt inhibits the expression of apoptosis-related proteins (eg, Bad and Bax) and promotes the expression of cell survival-related proteins (e.g., Bcl-xl, and Bcl-2), thus enhancing the survival of cancer cells. MSLN can also regulate the proliferation and migration of cancer cells by activating the ERK 1/2 (extracellular signal-regulated kinase1/2) signaling pathway. MSLN may also affect the biological behavior of cancer cells by activating the JNK (c-Jun N-terminal kinase) signaling pathway.

At present, various drugs targeting MSLN/Mesothelin are constantly under development, and taking drugs alone or together with other products to treat diseases has become a new method and remarkable achievements have been made. MSLN/Mesothelin protein has shown important research value and application prospects in tumor biology, and drug research and development. With further research and technological advances, MSLN/Mesothelin protein products are also essential.Alpha Lifetech can provide MSLN/Mesothelin corresponding products and help each customer's research and development. In addition, Alpha Lifetech also provides advanced expression systems and purification services to accelerate antibody research and development. Our synthesized antibody expression undergoes rigorous quality validation, including sequencing validation and functional expression analysis, to ensure high fidelity and performance. In addition, Alpha Lifetech provides customized solutions for recombinant proteins, such as codon optimization, promoter selection, and vector design, supplemented by downstream applications such as protein expression analysis to meet specific experimental needs.